AI Science Tracker

Discovery of Dual FGFR4 and EGFR Inhibitors by Machine Learning and Biological Evaluation.

China Pharmaceutical University; State Key Laboratory of Natural Medicine · 14 Sep 2020 · medicine

Discovery

Discovery of Dual FGFR4 and EGFR Inhibitors by Machine Learning and Biological Evaluation.

Source check: Needs source check. Not independent scientific confirmation.

Finding: Four machine-learning methods were compared; the selected SVM models screened in-house compounds for dual FGFR4/EGFR inhibition. The primary abstract reports compound 1 kinase IC50 values of 86.2 and 83.9 nM, respectively. This assay result does not establish clinical efficacy.

Technology: Support-vector-machine activity models

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

AI contribution
SVM, random forest, gradient-boost regression tree and XGBoost models were compared after mutual-information feature selection; the best-performing SVM models predicted activity of in-house compounds.
Test and result
The primary abstract reports four QSAR methods and a selected dual inhibitor with IC50 86.2 nM for FGFR4 and 83.9 nM for EGFR. Assay denominator, comparator, and cell-level validation details were not present in the reviewed abstract; full ACS text was inaccessible.
Limitation / still unknown
Full Methods and biological-evaluation details were not reviewed. The date is unresolved: ACS header September 14 versus publication-history September 24 and PubMed Epub September 23, 2020.
Evidence sources and annotation context

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

Evidence sources: https://doi.org/10.1021/acs.jcim.0c00652

Needs source check · editorial details

The source has not been fully checked or contains conflicting information. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 18 Nov 2026. Review scope: Indexed primary ACS/PubMed abstract and conflicting publication metadata; complete Methods/Results not reviewed..

No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.

Editorial assessment: Impact 2/5 · Validation 3/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Open in the full catalog for filters, charts and related discoveries. Browse medicine discoveries.

Related catalog entries

Links use documented relationships where available, plus shared catalog context. A shared topic or model family does not establish a scientific dependency.